Catalent Pharma Solutions announced the completion of the first phase of a US$7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.
The first phase of investment, which was completed in August 2018, witnessed the expansion and upgrade of the facility's integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines.
The second phase of the investment will add four encapsulation lines, which will bring the total number of lines to 23.
It will significantly expand production, drying, and inspection capacity for nutritional supplements and beauty softgels at the site.
It is expected that these four new lines will be fully operational by January 2019.
The investment is driven by increasing demand for nutritional and beauty products globally.
It will also enable Catalent to better serve these markets.
|Name||Catalent Pharma Solutions|
|Parties Involved||Catalent Pharma Solutions|
|Schedule||Scheduled to be operational by 2019|